Primaquine for Prevention of Malaria in Travelers

Baird, J. Kevin; Fryauff, David J.; Hoffman, Stephen L.
December 2003
Clinical Infectious Diseases;12/15/2003, Vol. 37 Issue 12, p1659
Academic Journal
An expanding risk and range of endemic malaria threatens travelers. Primaquine is an old drug recently demonstrated to offer effective prophylaxis. Clinical trials conducted in Indonesia, Kenya, and Colombia showed that a primaquine base (30 mg per day) had protective efficacy against Plasmodium falciparum and Plasmodium vivax of 85%-93%. Among 339 children (age, >8 years) and adults taking this regimen for 12- 52 weeks, there was no greater risk of adverse symptomatic events among primaquine users than among recipients of placebo in double-blind studies. Among 151 subjects evaluated after 20 or 52 weeks of daily primaquine therapy, methemoglobinemia was found to be mild (<13%; typically <6%) and transient (duration, <2 weeks). We consider primaquine base (0.5 mg/kg per day consumed with food) to be safe, well-tolerated, and effective prophylaxis against malaria for nonpregnant persons and those with normal glucose-6-phosphate dehydrogenase levels. Primaquine's major advantage over most drugs for chemoprophylaxis is that it does not have to be taken before entering or beyond 3 days after leaving a malarious area.


Related Articles

  • The evolution of tafenoquine--antimalarial for a new millennium? Peters, Wallace // Journal of the Royal Society of Medicine;Jul1999, Vol. 92 Issue 7, p345 

    The article discusses the therapeutic potentials of tafenoquine, a novel drug developed by the antimalarial drug project of the Walter Reed Army Institute in the United States. The drug is evaluated as a long-acting chemoprophylactic for non-immune travelers and as an agent for the treatment of...

  • The burden of Plasmodium vivax relapses in an Amerindian village in French Guiana. Nacher, Mathieu; Stefani, Aurelia; Basurko, Celia; Lemonnier, Delphine; Djossou, Félix; Demar, Magalie; Elenga, Narcisse; Brousse, Paul; Ville, Muriel; Carme, Bernard // Malaria Journal;2013, Vol. 12 Issue 1, p1 

    Malaria is a public health problem in French Guiana. Plasmodium vivax is the most frequent parasite. The objective of this analysis was to estimate the proportion of relapses in the burden of vivax malaria using the statistical rule stating that any case of vivax malaria occurring less than 90...

  • Primaquine treatment for Plasmodium vivax - an essential tool for malaria control and elimination in Papua New Guinea. BETUELA, INONI; ROBINSON, LEANNE J.; HETZEL, MANUEL W.; LAMAN, MOSES; SIBA, PETER M.; BASSAT, QUIQUE; MUELLER, IVO // Papua New Guinea Medical Journal;Mar-Dec2014, Vol. 57 Issue 1-4, p68 

    Plasmodium vivax is a major cause of malarial infection and disease in young children in Papua New Guinea. Recent increase in funding for malaria control has improved accessibility to preventive measures, diagnosis and artemisinin combination therapies. Yet the current treatment and control...

  • Severe disease in children hospitalized with a diagnosis of Plasmodium vivax in south-eastern Pakistan. Shaikh, Salma; Memon, Hafeezullah; Iohano, Bhagchand; Shaikh, Amna; Ahmed, Imran; Baird, J Kevin // Malaria Journal;2012, Vol. 11 Issue 1, p144 

    Background: Infection by Plasmodium vivax has been considered rarely threatening to life, but recent studies challenge this notion. This study documented the frequency and character of severe illness in paediatric patients admitted to a hospital in south-eastern Pakistan with a...

  • Estimating the malaria transmission of Plasmodium vivax based on serodiagnosis. Jung-Yeon Kim; Hyung-Hwan Kim; Byoung-Kuk Na; Yeon-Joo Kim; Youngjoo Sohn; Hyuck Kim; Tong-Soo Kim; Hyeong-Woo Lee // Malaria Journal;2012, Vol. 11 Issue 1, p257 

    Background: Plasmodium vivax re-emerged in 1993 and has now become a major public health problem during the summer season in South Korea. The aim of this study was to interpret and understand the meaning of seroepidemiological studies for developing the best malaria control programme in South...

  • Directly-observed therapy (DOT) for the radical 14-day primaquine treatment of Plasmodium vivax malaria on the Thai-Myanmar border. Takeuchi, Rie; Lawpoolsri, Saranath; Imwong, Mallika; Kobayashi, Jun; Kaewkungwal, Jaranit; Pukrittayakamee, Sasithon; Puangsa-art, Supalap; Thanyavanich, Nipon; Maneeboonyang, Wanchai; Day, Nicholas P. J.; Singhasivanon, Pratap // Malaria Journal;2010, Vol. 9, p308 

    Background: Plasmodium vivax has a dormant hepatic stage, called the hypnozoite, which can cause relapse months after the initial attack. For 50 years, primaquine has been used as a hypnozoitocide to radically cure P. vivax infection, but major concerns remain regarding the side-effects of the...

  • Relapse of imported Plasmodium vivax malaria is related to primaquine dose: a retrospective study. Townell, Nicola; Looke, David; McDougall, David; McCarthy, James S. // Malaria Journal;2012, Vol. 11 Issue 1, p214 

    Background: Relapsing Plasmodium vivax infection results in significant morbidity for the individual and is a key factor in transmission. Primaquine remains the only licensed drug for prevention of relapse. To minimize relapse rates, treatment guidelines have recently been revised to recommend...

  • Repeated Plasmodium vivax malaria relapses in a Peruvian sailor. McFarland, Adam P.; Sanchez, Juan F.; Mercado, Alejandro; Ventocilla, Julio A.; Cavalcanti, Sofia; Gonzalez, Sofia; Lescano, Andres G. // Malaria Journal;12/1/2015, Vol. 14 Issue 1, p1 

    Two Plasmodium vivax recurrences in a Peruvian sailor with weight above the 60 kg (cap for primaquine dosage) highlight the importance of adequate radical cure weight dosage for patient treatment and control efforts, particularly within the military.

  • Unexpectedly long incubation period of Plasmodium vivax malaria, in the absence of chemoprophylaxis, in patients diagnosed outside the transmission area in Brazil. Brasil, Patrícia; de Pina Costa, Anielle; Pedro, Renata Saraiva; da Silveira Bressan, Clarisse; da Silva, Sidnei; Tauil, Pedro Luiz; Daniel-Ribeiro, Cláudio Tadeu // Malaria Journal;2011 Supplement 1, Vol. 10 Issue Suppl 1, p122 

    Background: In 2010, Brazil recorded 3343,599 cases of malaria, with 99.6% of them concentrated in the Amazon region. Plasmodium vivax accounts for 86% of the cases circulating in the country. The extra-Amazonian region, where transmission does not occur, recorded about 566 cases imported from...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics